| Literature DB >> 35564732 |
Rafael Timon1, Adrián González-Custodio1, Aldo Vasquez-Bonilla1, Guillermo Olcina1, Alejo Leal2.
Abstract
Aging is associated with metabolic alterations, and with a loss of strength, muscle and bone mass. Moderate intermittent hypoxia has been proposed as a new tool to enhance health-related function. The aim of this study was to evaluate the effect of moderate intermittent hypoxia exposures on parameters related to cardiovascular and bone health in older adults. A total of 38 healthy older adults (aged 65-75 years) were divided into two groups: control group (C), and hypoxia group (H) that was subjected to an intermittent hypoxia exposure (at simulated altitude of 2500 m asl) during a 24-week period (3 days/week). Body composition, blood pressure, metabolic parameters (Cholesterol, triglycerides and glucose), C-reactive protein (CRP), vascular cell adhesion molecule-1 (VCAM-1), interleukin 8 (IL-8), interleukin 10 (IL-10), N-terminal propeptide of type I procollagen (PINP) and beta C-terminal telopeptide of collagen bone formation (b-CTX) were analyzed before and after the intervention. A repeated measures analysis of variance was performed to evaluate between-group differences. The results showed that the hypoxia group achieved after the intervention a decrease in fat mass, CRP (pro-inflammatory biomarker) and b-CTX (bone resorption biomarker), as well as an increase in PINP (bone formation biomarker). In conclusion, the intermittent hypoxia might be a useful therapeutic tool to deal with problems associated with aging, such as the increase in body fat, the loss of bone mass or low-grade inflammation.Entities:
Keywords: bone; fat mass; hypoxia exposure; inflammatory biomarkers; older adults
Mesh:
Substances:
Year: 2022 PMID: 35564732 PMCID: PMC9103404 DOI: 10.3390/ijerph19095339
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Characteristic of participants and control variables before of intervention (mean ± SD).
| Group | Sex | Years | Weight (kg) | Height (m) | Kcal/Day | Vit D (IU/Day) | Calcium (mg/Day) |
|---|---|---|---|---|---|---|---|
|
| 8 (M) | 70.5 ± 4.0 | 66.1 ± 10.2 | 1.56 ± 0.09 | 1941.5 ± 306.1 | 354.3 ± 90.3 | 892.5 ± 36.0 |
|
| 7 (M) | 70.2 ± 3.1 | 77.4 ± 11.2 | 1.66 ± 0.08 | 2015.0 ± 101.8 | 349.5 ± 16.2 | 846.1 ± 162.6 |
M: Male, F: Female.
Anthropometric, body composition and cardiovascular parameters at baseline and after 24 weeks of intervention.
| Baseline | 24 Weeks | ∆ (%) |
| ES (η2) | ANOVA | |
|---|---|---|---|---|---|---|
|
| 1.93 (0.174) | |||||
| Control | 66.1 ± 10.2 | 66.3 ± 10.2 | +0.3 | 0.582 | 0.014 | |
| Hypoxia | 77.4 ± 11.2 | 76.8 ± 10.5 | +0.7 | 0.188 | 0.054 | |
|
| 2.15 (0.152) | |||||
|
| 26.8 ± 2.6 | 26.9 ± 2.7 | +0.3 | 0.476 | 0.016 | |
|
| 27.9 ± 3.4 | 27.7 ± 3.07 | −0.7 | 0.199 | 0.051 | |
|
| 0.11 (0.741) | |||||
|
| 42.8 ± 10.1 | 43.1 ± 10.3 | +0.7 | 0.448 | 0.018 | |
|
| 47.1 ± 11.1 | 47.5 ± 11.1 | +0.8 | 0.289 | 0.035 | |
|
| 69.81 (0.001) + | |||||
|
| 25.3 ± 5.6 | 27.0 ± 5.9 | +6.7 | 0.001 * | 0.418 | |
|
| 30.5 ± 7.5 | 27.5 ± 7.1 | −9.8 | 0.001 * | 0.597 | |
|
| 1.98 (0.168) | |||||
|
| 2.36 ± 0.43 | 2.37 ± 0.45 | +0.4 | 0.300 | 0.033 | |
|
| 2.63 ± 0.45 | 2.62 ± 0.44 | −0.3 | 0.345 | 0.028 | |
|
| 1.87 (0.181) | |||||
|
| 0.96 ± 0.14 | 0.97 ± 0.12 | +1.0 | 0.658 | 0.006 | |
|
| 1.00 ± 0.13 | 0.99 ± 0.12 | −1.0 | 0.168 | 0.058 | |
|
| 0.70 (0.409) | |||||
|
| 63.9 ± 9.7 | 64.4 ± 8.9 | +0.7 | 0.615 | 0.008 | |
|
| 64.5 ± 9.5 | 63.7 ± 10.2 | +1.2 | 0.509 | 0.014 | |
|
| 1.37 (0.250) | |||||
|
| 128.0 ± 14.9 | 126.7 ± 17.5 | −1 | 0.671 | 0.006 | |
|
| 138.7 ± 14.9 | 132.1 ± 13.9 | −4.7 | 0.068 | 0.100 | |
|
| 2.05 (0.162) | |||||
| Control | 75.2 ± 9.2 | 75.0 ± 12.1 | −0.2 | 0.898 | 0.001 | |
| Hypoxia | 74.5 ± 8.0 | 70.0 ± 9.4 | −6 | 0.057 | 0.109 |
BMI: body mass index, BMC: bone mineral content; BMD: bone mineral density; HR: Heart rate; SBP: Systolic blood pressure; DBP; Diastolic blood pressure. * Significant differences with baseline values. + Significant differences between groups (Control vs. Hypoxia).
Blood parameters at baseline and after 24 weeks of intervention.
| Baseline | 24 Weeks | ∆ (%) |
| ES | ANOVA | |
|---|---|---|---|---|---|---|
|
| 0.86 (0.360) | |||||
|
| 99.6 ± 11.3 | 98.8 ± 10.2 | −0.8 | 0.607 | 0.008 | |
|
| 87.5 ± 12.0 | 84.3 ± 9.7 | −3.6 | 0.110 | 0.078 | |
|
| 0.02 (0.875) | |||||
|
| 90.5 ± 42.7 | 92.7 ± 44.4 | +2.4 | 0.602 | 0.009 | |
|
| 94.5 ± 31.8 | 95.8 ± 35.2 | +1.3 | 0.816 | 0.002 | |
|
| 0.01 (0.907) | |||||
|
| 186 ± 21.2 | 183.0 ± 20.4 | −1.6 | 0.398 | 0.022 | |
|
| 176 ± 41.7 | 172.3 ± 37.4 | −2.1 | 0.391 | 0.023 | |
|
| 1.61 (0.213) | |||||
|
| 70.3 ± 13.4 | 67.0 ± 13.1 | −4.6 | 0.086 | 0.158 | |
|
| 66.8 ± 12.5 | 64.3 ± 11.6 | −3.7 | 0.109 | 0.098 | |
|
| 5.72 (0.023) + | |||||
| Control | 67.5 ± 18.1 | 64.8 ± 19.9 | −3.9 | 0.612 | 0.008 | |
| Hypoxia | 76.9 ± 22.2 | 93.5 ± 19.6 | +21.6 | 0.011 * | 0.185 | |
|
| 4.91 (0.034) + | |||||
|
| 106.6 ± 38.8 | 112.5 ± 33.7 | +5.5 | 0.313 | 0.032 | |
|
| 101.8 ± 26.0 | 87.7 ± 27.0 | −13.8 | 0.049 * | 0.114 | |
|
| 4.48 (0.042) + | |||||
|
| 6.8 ± 1.4 | 6.7 ± 1.7 | −1.4 | 0.763 | 0.003 | |
|
| 6.1 ± 0.8 | 4.9 ± 1.4 | −19.6 | 0.005 * | 0.221 | |
|
| 1.53 (0.225) | |||||
|
| 485.9 ± 202.9 | 529.6 ± 214.4 | +8.9 | 0.115 | 0.076 | |
|
| 425.2 ± 124.2 | 416.9 ± 126.2 | −1.9 | 0.797 | 0.002 | |
|
| 0.70 (0.407) | |||||
|
| 1.7 ± 0.3 | 1.6 ± 0.4 | −5.8 | 0.115 | 0.078 | |
|
| 1.7 ± 0.4 | 1.7 ± 0.4 | 0 | 0.698 | 0.003 | |
|
| 0.41 (0.527) | |||||
|
| 2.2 ± 1.1 | 2.2 ± 1.0 | 0 | 0.947 | 0.001 | |
| Hypoxia | 2.1 ± 0.7 | 2.2 ± 0.7 | +4.5 | 0.442 | 0.019 |
CHO: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; PINP: N-terminal propeptide of type I procollagen; b-CTX: Beta C-terminal telopeptide of collagen; CRP: C-reactive protein; VCAM-1: Vascular cell adhesion molecule-1; IL-10: Interleukin 10; IL-8: Interleukin 8. * Significant differences with baseline values. + Significant differences between groups (Control vs. Hypoxia).